BianoScience
BianoGMP GmbH is a biotech company specializing in oligonucleotide manufacturing, analytics, and GMP services. Founded in 2011 as a spin-off from Friedrich-Schiller-University of Jena, it has developed a therapeutic RNAi platform and expanded its GMP oligonucleotide services. The company is committed to high-quality production for research and clinical applications, supporting projects from early-stage research to later clinical development. It has GMP-certified facilities and collaborates with EUROAPI for large-scale production. The company's mission is to support human health through advanced oligonucleotide solutions.
Industries
Nr. of Employees
small (1-50)
BianoScience
Ronneburger Straße 74, 07546 Gera, Germany
Patents
Biologically active molecules for influencing virus-, bacteria-, parasite-infected cells and/or tumor cells and method for the use thereof
US-9353369-B2
View DetailsBiologically active molecules, particularly based on PNA and siRNA, method for the cell-specific activation thereof, and application kit to be administered
US-9347060-B2
View DetailsCell-specifically effective molecules on the basis of siRNA and application kits for the production thereof and use thereof
US-9315808-B2
View Details
Biologically active molecules for influencing virus-, bacteria-, parasite-infected cells and/or tumor cells and method for the use thereof
US-9353369-B2
View DetailsBiologically active molecules, particularly based on PNA and siRNA, method for the cell-specific activation thereof, and application kit to be administered
US-9347060-B2
View DetailsCell-specifically effective molecules on the basis of siRNA and application kits for the production thereof and use thereof
US-9315808-B2
View DetailsProducts
Protease-activated RNAi prodrug platform
A therapeutic RNAi prodrug concept consisting of a chimeric siRNA deactivated by a peptide cap that is cleaved by disease-specific proteases to activate the siRNA selectively in diseased tissue; intended for anticancer and antiviral applications.
Protease-activated RNAi prodrug platform
A therapeutic RNAi prodrug concept consisting of a chimeric siRNA deactivated by a peptide cap that is cleaved by disease-specific proteases to activate the siRNA selectively in diseased tissue; intended for anticancer and antiviral applications.
Services
GMP-compliant manufacture of therapeutic oligonucleotides for early clinical trials, including GMP QC and documentation.
Small- and intermediate-scale oligonucleotide synthesis for R&D, assay development and early-stage projects.
Validated analytical testing and method development for identity, purity, impurity profiling, structural characterization and stability.
Process optimization, scale-up/scale-down, process transfer and process characterization including DOE and process validation services.
Support for ADME/pharmacology studies, dose-range finding, analytical method validation, life-cycle management and design of preclinical/clinical trials.
Project coordination, partner identification for formulation, fill & finish and clinical studies, and cooperative transfer to large-scale CDMO partners for later-phase development.
GMP-compliant manufacture of therapeutic oligonucleotides for early clinical trials, including GMP QC and documentation.
Small- and intermediate-scale oligonucleotide synthesis for R&D, assay development and early-stage projects.
Validated analytical testing and method development for identity, purity, impurity profiling, structural characterization and stability.
Process optimization, scale-up/scale-down, process transfer and process characterization including DOE and process validation services.
Support for ADME/pharmacology studies, dose-range finding, analytical method validation, life-cycle management and design of preclinical/clinical trials.
Project coordination, partner identification for formulation, fill & finish and clinical studies, and cooperative transfer to large-scale CDMO partners for later-phase development.
Expertise Areas
- Oligonucleotide therapeutics manufacturing
- Oligonucleotide analytical development
- GMP manufacturing and quality control
- Process development and scale-up
Key Technologies
- Solid-phase oligonucleotide synthesis
- Automated parallel synthesizers (multi-plate synthesis up to mmol scale)
- Preparative HPLC
- Cross-flow (tangential) filtration
News & Updates
BianoGMP's labs are GMP-certified by German authorities for manufacturing and quality control of therapeutic oligonucleotides.
BianoGMP's labs are GMP-certified by German authorities for manufacturing and quality control of therapeutic oligonucleotides.